Truseltiq
Truseltiq (infigratinib) is used to treat bile duct cancer (cholangiocarcinoma) in adults. It was approved by the FDA in 2021 under accelerated approval based on its potential benefit in adults with previously treated bile duct cancer that can't be surgically removed. This medication has been discontinued and will no longer be available in the United States after March 2023.
What is Truseltiq (infigratinib)?
What is Truseltiq (infigratinib) used for?
- Bile duct cancer
Drug facts
Get your GoodRx coupon
Common questions about Truseltiq (infigratinib)
Truseltiq (infigratinib) is a capsule that's taken by mouth used to treat certain types of bile duct cancer in adults who've already tried different therapies. This medication is a type of kinase inhibitor. It works by blocking signals in cancer cells that prevents them from growing and surviving. Truseltiq (infigratinib) was approved by the FDA based on an early clinical study showing that 23% of people who took Truseltiq (infigratinib) had a response to the medication. This means their cancer shrunk or disappeared after the treatment. Out of the people whose cancer responded to the medication, 32% of them maintained this response for 6 months or more.
According to the manufacturer (Helsinn), Truseltiq (infigratinib) will be available until March 2023. After this time, the medication will no longer be available in the United States.
The manufacturer (Helsinn) states that Truseltiq (infigratinib) was discontinued because researchers couldn't get enough people with bile duct cancer to participate in their clinical studies. The purpose of the studies was to confirm the medication's clinical benefit — how well the cancer responded to Truseltiq (infigratinib) and how long this response lasted. When a medication is granted an accelerated approval, the FDA requires the manufacturer to confirm the medication's clinical benefit through studies at a later time for consideration for a traditional approval. Truseltiq (infigratinib) wasn't discontinued because of safety reasons or because the medication didn't work well. If you have questions, speak to your healthcare provider.
How to save using GoodRx
Truseltiq (infigratinib) dosage
Dose pack| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 42 capsules of 125mg daily dose | 1 dose pack | $21,678.25 | $21,678.25 |
| 21 capsules of 100mg daily dose | 1 dose pack | $21,678.25 | $21,678.25 |
| 63 capsules of 75mg daily dose | 1 dose pack | $14,454.25 | $14,454.25 |
| 42 capsules of 50mg daily dose | 1 dose pack | $21,678.25 | $21,678.25 |
Typical dosage for Truseltiq (infigratinib)
How much does Truseltiq (infigratinib) cost?
$14,454.25
